Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

62.37
-2.3550-3.64%
Post-market: 62.370.00000.00%19:43 EDT
Volume:1.46M
Turnover:92.75M
Market Cap:1.79B
PE:-135.54
High:65.71
Open:64.47
Low:61.61
Close:64.72
52wk High:68.39
52wk Low:15.40
Shares:28.75M
Float Shares:17.26M
Volume Ratio:2.09
T/O Rate:8.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4601
EPS(LYR):-0.4601
ROE:-24.49%
ROA:7.06%
PB:48.18
PE(LYR):-135.54

Loading ...

Wedbush Raises Price Target on AnaptysBio to $60 From $50, Keeps Outperform Rating

MT Newswires Live
·
Mar 04

AnaptysBio : Barclays Raises Target Price to $79 From $78

THOMSON REUTERS
·
Mar 04

AnaptysBio price target raised to $66 from $51 at H.C. Wainwright

TIPRANKS
·
Mar 04

U.S. RESEARCH ROUNDUP-CrowdStrike, Oracle, Vulcan Materials

Reuters
·
Mar 04

AnaptysBio to Spin Off Biopharma Portfolio

Dow Jones
·
Mar 04

AnaptysBio Q4 Swings to Profit, Revenue Rises

MT Newswires Live
·
Mar 04

AnaptysBio's Q4 collaboration revenue more than doubled; details spin-off plan

Reuters
·
Mar 04

AnaptysBio provides update on potential spin-off of biopharma operations

TIPRANKS
·
Mar 04

BRIEF-AnaptysBio Q4 Net Income USD 49.614 Million

Reuters
·
Mar 04

AnaptysBio Q4 Collaboration Revenue USD 108.249 Million

THOMSON REUTERS
·
Mar 04

Press Release: Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Dow Jones
·
Mar 04

Eric J. Loumeau, Chief Legal Officer, Reports Disposal of AnaptysBio Inc. Common Shares

Reuters
·
Feb 14

Is It Time To Reassess AnaptysBio (ANAB) After A 198% One-Year Share Price Surge

Simply Wall St.
·
Feb 06

AnaptysBio kündigt Abspaltung von Biopharma-Geschäft und Royalty-Vermögenswerten bis Ende 2026 an

Reuters
·
Feb 06

AnaptysBio Is Maintained at Overweight by Barclays

Dow Jones
·
Jan 21

Barclays Sticks to Their Buy Rating for AnaptysBio (ANAB)

TIPRANKS
·
Jan 20

U.S. RESEARCH ROUNDUP-Alphabet, Micron Technology, Microsoft

Reuters
·
Jan 20

AnaptysBio Director Magda Marquet Reports Disposal of Common Shares

Reuters
·
Jan 17

What AnaptysBio (ANAB)'s Royalty Spin-Off Plan Means For Shareholders

Simply Wall St.
·
Jan 10

AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties

Benzinga_recent_news
·
Jan 10